LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

Начало・Списък с акции・Editas Medicine Inc

Editas Medicine Inc

Затворен

СекторЗдравеопазване

2.63 13.85

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

2.31

Максимум

2.76

Ключови измерители
By Trading Economics
Приходи	28M -25M
Продажби	4M 7.5M
Марж на печалбата	-332.984
Служители	246
EBITDA	27M -22M

Препоръки
By TipRanks
Препоръки	Неутрален
12-месечна прогноза	+100% upside

Дивиденти
By Dow Jones
Следващи печалби	11.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-65M 210M
Предишно отваряне	-11.22
Предишно затваряне	2.63

Настроения в новините

By Acuity

86%

14%

326 / 351 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

1.33 / 1.54 Подкрепа & съпротива

Editas Medicine Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

9.03.2026 г., 18:13 ч. UTC

Придобивния, сливания и поглъщания

Shell to Sell Jiffy Lube to Monomoy in $1.3 Billion Deal -- Update

9.03.2026 г., 17:20 ч. UTC

Значими събития в новините

U.S. Ag Industry Calls for Government Intervention on Fertilizer Prices

9.03.2026 г., 17:15 ч. UTC

Придобивния, сливания и поглъщания

Shell to Sell Jiffy Lube and Premium Velocity to Monomoy for $1.3 Billion

10.03.2026 г., 00:00 ч. UTC

Значими събития в новините

Why Iranian Regime Change Would Transform Global Energy Markets -- WSJ

9.03.2026 г., 23:52 ч. UTC

Пазарно говорене

Gold Steady; May Be Supported by Dollar's Weakness -- Market Talk

9.03.2026 г., 23:50 ч. UTC

Пазарно говорене

Nikkei May Rise as Fears About Higher Energy Prices Ease -- Market Talk

9.03.2026 г., 23:50 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

9.03.2026 г., 23:46 ч. UTC

Пазарно говорене

Значими събития в новините

Correction to Crude Prices Market Talk on March 9

9.03.2026 г., 23:42 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Futures Fall Amid Developments That Could Help Supply -- Market Talk

9.03.2026 г., 23:08 ч. UTC

Значими събития в новините

Front-Month WTI Futures Drop 7.9% to $87.29/bbl, ICE Data Show

9.03.2026 г., 23:07 ч. UTC

Значими събития в новините

Front-Month WTI Futures Fall After Trump Says Iran War Will Be Over 'Very Soon'

9.03.2026 г., 21:29 ч. UTC

Придобивния, сливания и поглъщания

Fortescue Now Fully Owns Peru's Canariaco Copper Project

9.03.2026 г., 21:28 ч. UTC

Придобивния, сливания и поглъщания

Fortescue Completes Acquisition of Remaining Alta Copper Shares

9.03.2026 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

9.03.2026 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

9.03.2026 г., 20:47 ч. UTC

Значими събития в новините

The 24 Hours When Oil Markets Went Wild -- WSJ

9.03.2026 г., 20:33 ч. UTC

Значими събития в новините

Stock Market Today: Oil Slips, Stocks Bounce on Trump War-Progress Comments Headline -- WSJ

9.03.2026 г., 20:14 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Moves Lower As Trump Says War Could End Soon -- Market Talk

9.03.2026 г., 19:33 ч. UTC

Значими събития в новините

High Oil Prices Could Crimp Convenience Store Margins -- Barrons.com

9.03.2026 г., 19:17 ч. UTC

Пазарно говорене

Значими събития в новините

Prospect of Added Supply From Oil Reserves Ease Inflation Fears -- Market Talk

9.03.2026 г., 19:14 ч. UTC

Пазарно говорене

Oil Settles Off Highs As G7 Discusses Tapping Reserves -- Market Talk

9.03.2026 г., 19:00 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Settle Lower -- Market Talk

9.03.2026 г., 18:23 ч. UTC

Пазарно говорене

Значими събития в новините

BofA Drops Canada Rate-Cut Call on Higher Oil Prices -- Market Talk

9.03.2026 г., 17:58 ч. UTC

Придобивния, сливания и поглъщания

Shell to Sell Jiffy Lube to Monomoy in $1.3B Deal -- Update

9.03.2026 г., 17:57 ч. UTC

Придобивния, сливания и поглъщания

Activist Investors Target Food Companies as Growth Slows. Lamb Weston Is the Latest. -- Barrons.com

9.03.2026 г., 17:41 ч. UTC

Значими събития в новините

U.S. and Western Allies Turn to Reserves to Counteract Gulf Oil Crisis -- WSJ

9.03.2026 г., 17:41 ч. UTC

Пазарно говорене

Значими събития в новините

Reports of Saudi Production Shut-Ins Keep Bid in Crude -- Market Talk

9.03.2026 г., 17:08 ч. UTC

Пазарно говорене

Canada Rate Outlook Shifts From Long Pause to Late 2026 Hike -- Market Talk

9.03.2026 г., 17:04 ч. UTC

Пазарно говорене

Значими събития в новините

Global Forex and Fixed Income Roundup: Market Talk

9.03.2026 г., 17:04 ч. UTC

Пазарно говорене

Значими събития в новините

Treasury Yields, Dollar Off Highs as G7 Tackles Oil Shock -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Editas Medicine Inc Прогноза

Ценова цел

By TipRanks

100% нагоре

12-месечна прогноза

Среден 4 USD 100%

Висок 4 USD

Нисък 4 USD

Според 3 анализатори от Wall Street, предложили 12-месечна ценова цел за Editas Medicine Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

3 ratings

Купи

Задържане

Продай

Според 3 анализатори, дали борсови рейтинги на Editas Medicine Inc през последните 3 месеца.

Техническа оценка

By Trading Central

1.33 / 1.54Подкрепа & съпротива

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

There are no events.

Настроение

By Acuity

326 / 351 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Editas Medicine Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.